MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Aug. 29, 2019 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will attend the following investor conferences in September:

• Citi 14th Annual Biotech Conference. MacroGenics’ management will participate in one-on-one meetings, as well as a webcast panel discussion titled “New Targets in Cancer Immunotherapy and the Tumor Microenvironment” in Boston, MA, on Wednesday, September 4, 2019, at 9:30 a.m. ET.
• H.C. Wainwright 21st Annual Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and a fireside chat with the analyst in New York City on Monday, September 9, 2019, at 12:50 p.m. ET.
• Morgan Stanley 17th Annual Global Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and a fireside chat with the analyst in New York City on Tuesday, September 10, 2019, at 10:35 a.m. ET.

Webcasts of the panel discussion and fireside chats may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days after the conference.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

You May Also Be Interested In

• Ruvi AI Surpasses 60% of Phase 4 as AI Crypto Presale Continues Rapid Momentum Following Record-Breaking Phase 3
• Lyt Inc. Launches LytSpace: Genome AI Configures Over 150 Sensors Autonomously, While Full-Resolution Biometric Data Is Preserved for Decades
• The ONE Music outlines a practical digital piano selection framework for advancing players